The Trump Administration is expected to issue an executive order this week reviewing the regulations governing the use of low- and moderate-risk products in the United States, Politico reported Wednesday.
The order, which the White House is expected, is expected by the end of June.
The move comes as the Trump administration struggles to implement a health care bill that many experts warn will cause billions in harm to the health care system, according to a report in Politico on Tuesday.
The report was based on a review of regulatory guidance and consumer protections published by the U.S. Centers for Disease Control and Prevention.
The Trump administration has been unable to find a replacement for the Affordable Care Act’s protections for consumers against the most common types of medical errors, such as drug and alcohol misuse and over-the-counter (OTC) prescription drugs.
As a result, the administration has struggled to implement policies that will allow consumers to safely access those products, the report said.
The review, however, is not expected to require the removal of any existing regulations, according the report.
Instead, it is expected that the order will focus on the use and regulation of low risk products that have been in place since 2014.
“The White House has been reluctant to review the regulations that apply to all forms of OTC prescription medications because they are designed to reduce drug-related harms,” the report stated.
The FDA, however is also expected to revise a number other rules, including the rule for electronic medical records (EMRs) and the rule to prohibit certain food and drug companies from marketing products that contain drugs. “
While there are a number of new FDA regulations that have not yet been finalized, the Administration has committed to reviewing existing regulations for OTC products in an effort to minimize the impact of the FDA’s new rules,” the White the report added.
The FDA, however is also expected to revise a number other rules, including the rule for electronic medical records (EMRs) and the rule to prohibit certain food and drug companies from marketing products that contain drugs.
The Office of Management and Budget is also reviewing the FDA regulations for high-tech manufacturing, which would include the requirement that certain high-technology manufacturing equipment be manufactured in a facility that is not certified for that use.
The Department of Agriculture (USDA) is also conducting a review to determine whether certain food products are labeled as high-impact, which could impact the use by consumers.